No Data
No Data
AbbVie Retains Humira Market Share Above 70%: Report
TD Cowen Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $19
Is Organon & Co. (OGN) the Best Medical Stock to Buy Under $20?
Organon Snaps Six Days of Winning Streak
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Goldman Sachs Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $20